Gilead Sciences, Inc. (NASDAQ:GILD) Director Nicholas G. Moore sold 20,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $84.05, for a total transaction of $1,681,000.00. The sale was disclosed in a document filed with the SEC. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened at $83.79 in last session, and closed at $82.79, while the day range of GILD stock is $81.80-$84.20.The stock showed a positive weekly performance of 0.24%.
The Dow component that led the way higher was Johnson & Johnson (NYSE:JNJ), which sported a 76-cent gain (+0.8%) bringing the stock to $92.12. This single gain lifted the Dow Jones Industrial Average by 5.75 points or roughly accounting for 11.7% of the Dow’s overall gain. Volume for Johnson & Johnson ended the day at 9.5 million shares traded vs. an average daily trading volume of 8.3 million shares. Johnson & Johnson (NYSE:JNJ) stock opened at $91.42, in last session and closed at $92.12, by gained 0.83%.The 52 week range was $75.73-$95.99.Company’s market capitalization is $260.60 billion.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock loosed -3.84% and finished the last session at $6.51.The EPS of the stock remained -0.08.Company’s market capitalization is $1.42 billion.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) was last seen up more than 5 percent to $8.99. A volume of more than 23 million shares were traded in the last session, making the stock one the notable movers on Nasdaq. The stock escalated to $9.05 in the day and touched a low of $8.22 by bell time in the regular session. ARIA recently released earnings for its fiscal 2013 fourth quarter which showed loss of 40 cents per share, bigger than the loss of 36 cents per share that was realized in the corresponding quarter in the previous year. However, the share loss per share was better than the 46 cents that Zacks estimated. As for revenue, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) generated $8.4 million, exceeding both a year ago figures and Zacks estimates of $0.07 million and $6 million respectively. The company reported 2013 loss of $1.49 per share, wider than the loss of $1.34 per share that was realized a year ago. Revenue for 2013 was $45.6 million, more than $43 million estimated by Zacks and $0.6 million noted in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened the session at $9.13, and closed the session at $8.69.The 52 week range of the ARIA stock remained $2.15-$23.00 and the day range was $8.55-$9.13.
Leave a Reply